A Phase II/III clinical trial of JR-051 with Fabry patients.
Phase of Trial: Phase II/III
Latest Information Update: 21 Sep 2018
At a glance
- Drugs Agalsidase beta (Primary)
- Indications Fabry's disease
- Focus Adverse reactions; Therapeutic Use
- 21 Sep 2018 According to a JCR Pharmaceuticals media release, based on this study, the company has received the marketing approval from the Ministry of Health, Labour and Welfare of Japan.
- 05 Oct 2017 New trial record